

# Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

## Anti-cdc2, phospho (Tyr15) Antibody, Unconjugated

RRID:AB\_331460

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 9111, RRID:AB\_331460

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_331460](http://antibodyregistry.org/AB_331460)

**Proper Citation:** Cell Signaling Technology Cat# 9111, RRID:AB\_331460

**Target Antigen:** cdc2, phospho (Tyr15)

**Clonality:** unknown

**Comments:** Applications: W, IP. Consolidation on 11/2018: AB\_10104768, AB\_10104769, AB\_10835695, AB\_2074655, AB\_331460.

**Antibody Name:** Anti-cdc2, phospho (Tyr15) Antibody, Unconjugated

**Description:** This unknown targets cdc2, phospho (Tyr15)

**Target Organism:** monkey, rat, simian, xenopus, mouse, human

**Antibody ID:** AB\_331460

**Vendor:** Cell Signaling Technology

**Catalog Number:** 9111

**Record Creation Time:** 20250819T233629+0000

**Record Last Update:** 20250820T055138+0000

---

### Ratings and Alerts

No rating or validation information has been found for Anti-cdc2, phospho (Tyr15) Antibody, Unconjugated.

No alerts have been found for Anti-cdc2, phospho (Tyr15) Antibody, Unconjugated.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 31 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Dommer AP, et al. (2026) Cyclin E modulates vulnerability to CDC7 kinase inhibition. *Oncogenesis*, 15(1).

Haykal MM, et al. (2025) Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers. *Cancer letters*, 620, 217665.

Kirichenko E, et al. (2025) Jub-induced phosphorylation of Warts inhibits its activity and recruitment into biomolecular condensates. *Cell reports*, 44(12), 116647.

Takacs L, et al. (2025) Evidence of substrate control of Cdk phosphorylation during the budding yeast cell cycle. *Cell reports*, 44(4), 115534.

Tan T, et al. (2025) Revisiting phosphoregulation of Cdc25C during M-phase induction. *iScience*, 28(1), 111603.

Marotta VE, et al. (2025) OTUD6B regulates KIFC1-dependent centrosome clustering and breast cancer cell survival. *EMBO reports*, 26(4), 1003.

Joo YK, et al. (2025) The mitotic ATR-Chk1 pathway promotes CDK1 activity for faithful chromosome segregation. *Cell reports*, 44(8), 116019.

Drainas AP, et al. (2024) GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer. *Cell reports*, 43(8), 114606.

Lim JS, et al. (2024) Energy?stress?mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple?negative breast cancer. *Oncology reports*, 52(2).

Santoni M, et al. (2024) Unraveling the interplay between PKA inhibition and Cdk1 activation during oocyte meiotic maturation. *Cell reports*, 43(2), 113782.

Dreyer J, et al. (2024) Acute multi-level response to defective de novo chromatin assembly in S-phase. *Molecular cell*, 84(24), 4711.

Xu N, et al. (2023) PUF60 promotes cell cycle and lung cancer progression by regulating alternative splicing of CDC25C. *Cell reports*, 42(9), 113041.

Petrosius V, et al. (2023) Temporal phosphoproteomics reveals WEE1-dependent control of 53BP1 pathway. *iScience*, 26(1), 105806.

Zhou C, et al. (2022) The oocyte spindle midzone pauses Cdk1 inactivation during fertilization to enable male pronuclear formation and embryo development. *Cell reports*,

39(5), 110789.

Elbæk CR, et al. (2022) WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity. *Cell reports*, 38(3), 110261.

Donker L, et al. (2022) A mechanical G2 checkpoint controls epithelial cell division through E-cadherin-mediated regulation of Wee1-Cdk1. *Cell reports*, 41(2), 111475.

Bose A, et al. (2021) 14-3-3 $\gamma$  prevents centrosome duplication by inhibiting NPM1 function. *Genes to cells : devoted to molecular & cellular mechanisms*, 26(6), 426.

Klomp JE, et al. (2021) CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. *Cell reports*, 37(9), 110060.

Branigan TB, et al. (2021) MMB-FOXO1-driven premature mitosis is required for CHK1 inhibitor sensitivity. *Cell reports*, 34(9), 108808.

Kamenz J, et al. (2021) Bistable, Biphasic Regulation of PP2A-B55 Accounts for the Dynamics of Mitotic Substrate Phosphorylation. *Current biology : CB*, 31(4), 794.